Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.62 |
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | CTSC | P53634 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31215109 | 1.00 | OPRD1 (0.62) | OPRD1OPRM1MMECTSCSLC6A2 | |
| SCHEMBL31215083 | 0.97 | OPRD1 (0.60) | OPRD1OPRM1MMECTSCSLC6A2 | |
| SCHEMBL31215084 | 0.95 | OPRD1 (0.62) | OPRD1OPRM1MMECTSCSLC6A2 | |
| SCHEMBL29823718 | 0.94 | OPRD1 (0.70) | OPRD1OPRM1MMESLC6A2OPRK1 | |
| SCHEMBL31174322 | 0.93 | MME (0.67) | OPRD1OPRM1MMECTSCLTA4H | |
| SCHEMBL8525810 | 0.93 | MME (0.67) | OPRD1OPRM1MMECTSCLTA4H | |
| SCHEMBL8525812 | 0.93 | MME (0.67) | OPRD1OPRM1MMECTSCLTA4H | |
| SCHEMBL30974432 | 0.91 | MME (0.56) | OPRD1OPRM1MMECTSCLTA4H | |
| SCHEMBL30504227 | 0.91 | OPRM1 (0.62) | OPRD1OPRM1MMELTA4H | |
| SCHEMBL30052163 | 0.91 | CTSD (0.54) | OPRD1OPRM1CTSCGNPATOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099867-A1 | SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-15 | — | — | WO | claimed |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-02-01 | — | — | US | claimed |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | claimed |
| WO-2026099867-A1 | SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-15 | — | — | WO | disclosed |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-02-01 | — | — | US | disclosed |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | OPRD1 749/4885OPRM1 475/4885MME 49/4885 |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | OPRD1 239/4885OPRM1 140/4885MME 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.